



IMMUNOHISTOCHEMICAL EXPRESSION OF SURVIVIN AND KI-67 AS TUMOR MARKERS IN BREAST CANCER INFECTED FEMALES: A CROSS-SECTIONAL STUDY

Afaf Almubark Ali Mohamed¹, Nazik Elmalaika Obaid², Sara Abdelghani³, Abdulaziz Alfahed⁴, Hisham Ali Waggiallah⁴, Lienda Bashier Eltayeb^{4*}

1. *Department of Histopathology, Faculty of Medical Laboratory Sciences and cytology, Faculty of Medical Laboratory Sciences, Omdurman Islamic University, Sudan.*
2. *Department of Pathology, Faculty of Medicine, Omdurman Islamic University, Sudan.*
3. *Department of parasitology, Faculty of Medical Laboratory Sciences, Al-Neelain University-Sudan.*
4. *Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Alkharj, Saudia Arabia.*

ARTICLE INFO

Received:
20 May 2020
Received in revised form:
15 Aug 2020
Accepted:
17 Sep 2020
Available online:
28 Oct 2020

Keywords: Breast cancer, Immunohistochemical, Survivin, Ki-67.

ABSTRACT

Survivin is a part of the apoptosis inhibitor group. It is implicated in the control of the cell division and is commonly distributed in fetal tissues and human tumors, and is never expressed in normal adult tissues. The present study aimed at evaluating Survivin and Ki-67 immunohistochemical expression in breast tumors among the Sudanese females. From a total of 200 archives of formalin-fixed paraffin-embedded (FFPE) tissue sections histologically diagnosed as breast tumor, 75% were malignant and 25% were benign. Immunohistochemical staining for Survivin, Ki-67 was done using the Avidin-Biotin Complex (ABC) method. Data were analyzed using SPSS version 26. Invasive ductal carcinoma was diagnosed in 82.7% of patients, about 44 % of them were grade III. A significant association of Survivin expression was revealed in (36.7%) of malignant samples; while (100%) of the benign tumor samples had a positive expression (P-value = 0.01). Ki-67 had a positive expression in 52% of the malignant cases and was not expressed in benign ones, (P-value = 0.000). Our study indicated that survivin was significantly expressed in all benign and around one-third of the malignant tumors that were correlated with tumor grades. There was also a significant direct proportion association between Ki-67 and tumor grades.

Copyright © 2013 - All Rights Reserved - Pharmacophore

To Cite This Article: Afaf Almubark Ali Mohamed, Nazik Elmalaika Obaid, Sara Abdelghani, Abdulaziz Alfahed, Hisham Ali Waggiallah, Lienda Bashier Eltayeb, (2020), "Immunohistochemical Expression of Survivin and Ki-67 as tumor markers in Breast Cancer infected females: A cross-sectional prospective study", *Pharmacophore*, 11(5), 41-45.

Introduction

Breast cancer is a disease in which breast tissue cells change and divide uncontrolled, usually leading to a mass or lump. Most breast cancers benign in the lobules or in the ducts that connect the lobules to the nipple [1, 2]. Breast tumors are two types: non-cancerous (benign) and cancerous (malignant). Breast cancer is the most prevalent cancer among women worldwide [3, 4]. Although many women fear cancer, most of the breast problems are not cancer. Malignant breast disease is any cancer that originates in the breast tissue; if left untreated it can metastasis to other organs in the body via the blood or the lymphatic system. Breast cancer is fatal in around one-third of cases [5]. Worldwide, it is a crucial health problem, with about 1,384,155 new cases and around 459,000 related deaths [6]. In a study from Sudan National Cancer Registry (NCR), 6771 incident cancer patients were recorded among the residents of Khartoum state [7]. The magnitude of breast cancer and the basic understanding of its initiation and progression is still incomplete. In Sudan, the extent of breast cancer is not an exception from other countries. The problem is aggravating by the lack of resources and effective screening programs, as well as presentations at a late stage. The development of enhanced methods is an urgent need to stratify breast cancer patients into different risk groups more accurately than can be achieved with current clinicopathological classification methods.

Corresponding Author: Lienda Bashier Eltayeb, PhD. Assistant Professor of Medical Microbiology, College of Applied Medical Sciences, Prince Sattam University, Al- Kharij-Riyadh, Saudi Arabia. Email: lindarose009 @ hotmail.com

Cancer cells can escape from apoptosis via allelic depletion of cell death activators [8], deregulated overexpression of apoptosis inhibitors, or inactivating mutations in executioner molecules of cell death. Survivin is a member of the inhibitors of apoptosis (IAP) family and is also involved in the regulation of cell division. Survivin, also known as BIRC5 or AP14, is a 16.5-KDA protein located in chromosome 17q25 [9]. It contains a domain of the baculovirus inhibitor of apoptosis protein repeat (BIR) that categorizes it as a member of the IAP family inhibitor. Through the BIR domain, Survivin inhibits apoptosis by directly or indirectly interfering with the functions of caspases [10]. It also plays a key role in proliferation by regulating mitosis [11]. The evaluation of the proliferative activity of tumors is very important in oncology [12] and is widely evaluated by the immunohistochemical assessment of the nuclear antigen Ki-67. It is a great marker for determining the growth fractions of a specific cell population because it measures the number of proliferating and dividing cells, which lead to an understanding of how fast a tumor is growing [13]. Ki-67 is expressed during the active phases of the cell cycle, namely G1, S, G2, and mitosis, so it is a proliferative index marker. Tumor proliferation activity, measured by Ki-67 antigen expression, is related to the tumor proliferation rate [12]. The application of Ki-67 antigen in oncology demonstrated the prognostic significance of the protein expression in various human malignant tumors, e.g. in multiple myeloma, soft tissue tumors, prostate tumors, and in mammary cancer [14]. This study aimed at evaluating Survivin and Ki-67 immunohistochemical expression in breast tumors among the Sudanese females.

Materials and Methods

Study design: A cross-sectional prospective study was done through the period from October 2017 to October 2019 on 200 archives of formalin-fixed paraffin-embedded (FFPE) tissue sections diagnosed histologically as breast tumors at the Histopathology and Cytology Laboratory, National Ribat University Hospital (NRUN), Sudan. All Blocks with deficient material and samples having poor records were excluded, also any section without breast tumor was excluded. For perfect quality control, all sections were checked by a professional histopathologist.

Sample technique and Sample size

The sampling technique was convenient simple random technique, sample size was calculated according to the formula:

$$\text{Sample size} = \frac{Z^2 \cdot p \cdot (1-p)}{d^2}$$

Z= level of confidence = 1.96

P= expected proportion in the study population according to previous studies.

d= absolute error.

For calculation

P=15.4%⁽⁶²⁾.

Then the calculation was $(1.96 \times 1.96) \cdot 0.154 \cdot (1 - 0.154) / 0.0025$

Sample size = 200.1 ~ 200

Methods

Immunohistochemical staining was carried out using indirect streptavidin-biotin immunoperoxidase technique briefly as follows: The tissue section was deparaffinized in 2 xylene changes for 5 minutes each, then rehydrated through descending concentration of ethanol (100%, 90%, 70%, and 50%) and water. Next, antigen retrieval was done by water bath technique for at 97°C thirty minutes (Coplins jar containing citrate buffer, pH 6.8). After that, samples were treated with a hydrogen peroxide solution for 10 min and then incubated in an optimally diluted primary antibody (anti survivin/Ki-67) for 30 min. The primary antibodies were provided from Zytomed, Germany. (Appendix 2). The samples were then incubated in an optimally diluted biotinylated secondary antibody for 15 min, followed by rinsing in phosphate buffer saline (PBS) (pH 7.4) and incubation in optimally prepared labeled avidin for 30 min. Afterward, they were washed in PBS (pH 7.4) for 5min and further incubated in DAB substrate solution. The slides were washed in running water and the counter was stained by Mayers haematoxylin for one minute, washed, and after that blueing was done in 0.05% ammoniated water for 16 seconds and then it was washed in tap water. Afterward, dehydration was done through ascending concentration of ethanol (50%, 70%, 90%, and 100%) and cleared in xylene and mounted in DPX mountant [14].

Statistical Analysis: SPSS version 26 was used for data analysis. In all procedures, $p \geq 0.05$ was considered the level of significance.

Ethical approval

This study was approved by the ethical committees at the Faculty of Laboratory Sciences Omdurman Islamic University and the National Ribat University Hospital. Informed consent was waived since patient's personal information was anonymized and only laboratory serial numbers were used. Permission was taken from the NRUH for the conduct of the research.

Results

200 samples were included in the study, 75% (n=150) of them diagnosed as malignant and the other 25% (n=50) were benign. The study population age ranged from 18 to 88 years old with a mean age of 46 ± 17.2 SD. Most of the patients

(n=36, 24%) were within the age group of 40 to 59 years. The distribution of age group according to tumor types was summarized in Table 1. The tumor types included invasive ductal carcinoma in 82.7%, invasive lobular carcinoma in 8.7%, medullary carcinoma in 5.3% samples, and mucinous carcinoma in 3.3%, while 25% had a benign tumor (Figure 1). The positive expression of Survivin was found in (36.7%) of malignant samples, while all benign tumor samples (100%) and 0/5(0%) of samples had a positive and negative expression, respectively. This result showed a significant association (P-value = 0.01) (Table 2).

Table (3) shows the correlation between the survivin expression and tumor grade among the studied Sudanese patients. The majority of samples significantly expressed survivin in grade III (44%), followed by grade II in 30.7% of samples (p-value =0.001). The correlation between the expression of Ki-67 with tumor grades among the studied Sudanese women showed a significant association (p-value=0.000). Ki-67 had a positive expression in 52% of the malignant cases, while none of the samples of the benign tumor were positive (Table 4).

Table (5) shows the significant association between survivin and Ki-67 in which expression of Ki-67 is less than 20% (n=9)7.4% positive, while expression of Ki-67 tumor marker is more than 20% (n=46) 59% positive. (p. value =0.00).

Table 1: Histological types of breast carcinoma among the study population.

Characteristics	Malignant tumor n=150 (%)	Benin tumor n=50 (%)	p. value
Less than 20 Years Old	5 (3.3%)	12 (24%)	0.005
20-39	12 (8%)	5 (10%)	
40-59	36 (24%)	24 (48%)	
60- 79	32 (21.3%)	8 (16%)	
More than 80	20 (13.3%)	1(2%)	
Total	150 (100%)	50 (100%)	




Figure 1: Percentage of types of malignant and benign tumors

Table 2: Frequency of Survivin among the malignant and benign tumors.

Survivin	Type		Total
	Malignant	Benign	
Positive	55(36.7%)	0(0%)	55
Negative	95(63.3%)	50 (100%)	145
Total	150(100%)	50 (100%)	200
P-value	0.01		

Table 3: The frequency and correlation between the expression of Survivin and tumor grade among the study participants with a malignant tumor.

Survivin	Grade				Total
	Grade I	Grade II	Grade III	Benign	
Positive	2	8	30	15	55 (36.7%)
Negative	10	38	36	61	145
Total	12	46	66	76	200
P-value	0.001				

Table 4: The correlation between the expression of Ki-67 with tumor grades among the studied Sudanese women

Ki-67	Grade				Total
	I	II	III	Benign	
More than 20%	10(5%)	26(13%)	25(12.5%)	61(30.5%)	122(61%)
Less than 20%	2(1%)	20(10%)	41(20.5%)	15(7.5%)	78(39%)
Total	12	46	66	76	200
P-value	0.000				

Table 5: Correlation of the expression of Survivin with Ki-67 marker.

Ki-67	Survivin		Total
	Positive	Negative	
Less than 20%	9	113	122
More than 20%	46	32	78
Total	55	145	200
p-value	0.000		

Discussion

This study involved 200 cases of breast tumors and studied immunohistochemically for Survivin, Ki-67, and hormonal status. Concerning the age groups of the study population, this study illustrated that the majority of patients who were aged above 40 years old are more susceptible to breast cancer due to endogenous hormone levels. The result of this study is compatible with McPherson et al. (2000) who reported that the incidence of breast cancer increases with age (P-value=0.001) and also well-matched with Kennedy et al. study in which they found (92) women were less than 50 years and (201) women were over 50 years at diagnosis [15]. The histological diagnosis of the study population revealed that the more frequent type is invasive ductal carcinoma (p-value=0.003). The result agrees with Al-Joudi [16] who reported that invasive ductal carcinoma of the breast is the most prevalent breast cancer type (p-value <0.001). Survivin expression was detected in 78.5 % (51/65) of breast carcinomas whereas no expression of Survivin was detected in the healthy breast tissue.

Another study done by Kennedy [15] showed a significant relationship between surviving and tumor type. (P-value =0.00). Also, this study agrees with Nahed [17] who reported a statistically significant relationship between Ki-67 and tumor grade (P-value=0.00). The same study showed a statistically significant relationship between HER2 and the grade of cancer (P-value=0.005). On the other hand, a study done by Margulis V [18] showed a statistically significant relationship between Ki-67, HER2, and PR (P-value=0.00). This study is also in agreement with a study done by Anna, [19] that showed a statistically significant association between the expression of PR, ER, and the grade of cancer (P-value= 0.01). The Survivin expression among malignant grades shows a high expression in grade III. This result is in line with Youssef, [20] who reported that Survivin expression showed a significant relationship with high histological grade (P.value=0.04). There is a statistically significant relationship between Survivin, which was detected in 78.5% (51/65) of breast carcinomas while no Survivin expression was observed in the adjacent normal breast tissue.

Conclusions

Survivin positive expression was significantly revealed in one-third of malignant samples, and all of the benign tumors. Moreover, Ki-67 positive expression was detected in most of the malignant cases, while it was not expressed in benign ones. There was a statistically significant association between Survivin, Ki-67, and malignant tumors grade, as well as hormonal status in malignant tumors.

Acknowledgement

This publication was supported by the Deanship of scientific research at Prince Sattam bin Abdulaziz University.

Conflict of interest statement: The authors declare that they have no conflict of interest.

Authors contribution

- AAM (sample collection and laboratory work, purchasing reagents and laboratory works)
- SA (Calibration of machines, preparation Study protocol and SOPs (Standard Operating Procedures))
- NAO (Supervision)
- HAW (proofreading and review)
- LBE (Scientific writing of manuscript)

References

1. William S. American Cancer Society. Breast Cancer Facts And Figures.2019-2020. Atlanta: American Cancer Society, Inc. 2019.
2. Abdallah NM, Eldin SA, Gad AH. Breast and Nipple Problems Encountered among Puerperal Primipara Women in Zagazig. *Int. J. Pharm. Res. Allied Sci.* 2018;7(1):183-95.
3. Kurdi L, Alhusayni F. Cytotoxicity effect of 5-fluorouracil and bee products on the MCF-7 Human Breast Cancer Cell Line in vitro. *Int. J. Pharm. Phytopharm. Res.* 2020;10(2):19-26.
4. Hosny G, Elkaffas SM. A prediction model for the incidence patterns of female breast cancers in Alexandria, Egypt. *The Journal of the Egyptian Public Health Association.* 2002 Jan 1;77(3-4):329-45.
5. Strydhorst JH. Breast Cancer Tomotherapy. The Impact of Intrafraction Motion and Shallow Depth Dose Profiles on the Choice of PTV Depth. Carleton University Ottawa.2008.
6. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. *Cell biochemistry and biophysics.* 2015 Jun 1;72(2):333-8.
7. Elamin A, Ibrahim ME, Abuidris D, Mohamed KE, Mohammed SI. Part I: cancer in Sudan—burden, distribution, and trends breast, gynecological, and prostate cancers. *Cancer medicine.* 2015 Mar;4(3):447-56.
8. Soengas MS, Capodiecici P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardó C. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. *Nature.* 2001 Jan;409(6817):207-11.
9. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. *Trends in molecular medicine.* 2001 Dec 1;7(12):542-7.
10. Chiou SK, Jones MK, Tarnawski AS. Survivin-an anti-apoptosis protein: its biological roles and implications for cancer and beyond. *Medical Science Monitor.* 2003 Apr 23;9(4):PI25-9.
11. Ranade K, Nerurkar A, Phulpagar M, Shirsat N. Expression of survivin and p53 proteins and their correlation with hormone receptor status in Indian breast cancer patients. *Indian journal of medical sciences.* 2009 Nov 1;63(11):481.
12. Bairey O. Role and Prognostic Significance of the Ki-67 Index in Non-Hodgkin's Lymphoma. *European Journal of Clinical & Medical Oncology.* 2010 Feb 1;2(1).
13. Naz E, Mirza T, Aziz S, Ali A, Danish F. Correlation of Ki 67 proliferative index with clinical and pathological features on tissue sections of non Hodgkins lymphoma by immunostaining. *JPMA-Journal of the Pakistan Medical Association.* 2011 Aug 1;61(8):748.
14. Szczuraszek K, Mazur G, JELEŃ M, DZIEGIEL P, Surowiak P, Zabel M. Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas. *Anticancer research.* 2008 Mar 1;28(2A):1113-8.
15. Bancroft JD. Theory and practice of histological techniques.8th edition. *Immunohistochemicals techniques.* 2010. Page 87.
16. Al-Joudi FS, Iskandar AZ, Hasnan J, Rusli J, Kamal Y, Imran AK, Ahmed M, Zakaria J. Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast. *Singapore medical journal.* 2007 Jul 1;48(7):607.
17. Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. *Cancer biology & medicine.* 2016 Dec;13(4):496.
18. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. *World journal of urology.* 2008 Feb 1;26(1):59-65.
19. Anna L, Git A. Breast cancer path way base analysis. 2015; 9(7):1481-1483.
20. Youssef NS, Hewedi IH, Abd Raboh NM. Immunohistochemical expression of survivin in breast carcinoma: relationship with clinicopathological parameters, proliferation and molecular classification. *Journal of the Egyptian National Cancer Institute.* 2008 Dec;20(4):348.